- Home
- ALLK vs ASRT Comparison
ALLK vs ASRT Comparison
Compare ALLK & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- ASRT
- Stock Information
- Founded
- ALLK 2012
- ASRT 1995
- Country
- ALLK United States
- ASRT United States
- Employees
- ALLK N/A
- ASRT N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ALLK Health Care
- ASRT Health Care
- Exchange
- ALLK Nasdaq
- ASRT Nasdaq
- Market Cap
- ALLK 22.5M
- ASRT 85.1M
- IPO Year
- ALLK 2018
- ASRT 1997
- Fundamental
- Price
- ALLK $0.25
- ASRT $0.81
- Analyst Decision
- ALLK Hold
- ASRT Strong Buy
- Analyst Count
- ALLK 3
- ASRT 4
- Target Price
- ALLK $2.00
- ASRT $3.19
- AVG Volume (30 Days)
- ALLK 4.8M
- ASRT 419.9K
- Earning Date
- ALLK 03-13-2025
- ASRT 03-10-2025
- Dividend Yield
- ALLK N/A
- ASRT N/A
- EPS Growth
- ALLK N/A
- ASRT N/A
- EPS
- ALLK N/A
- ASRT N/A
- Revenue
- ALLK N/A
- ASRT $125,763,000.00
- Revenue This Year
- ALLK N/A
- ASRT N/A
- Revenue Next Year
- ALLK N/A
- ASRT $1.84
- P/E Ratio
- ALLK N/A
- ASRT N/A
- Revenue Growth
- ALLK N/A
- ASRT N/A
- 52 Week Low
- ALLK $0.23
- ASRT $0.73
- 52 Week High
- ALLK $1.69
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- ALLK 28.77
- ASRT 43.42
- Support Level
- ALLK $0.23
- ASRT $0.79
- Resistance Level
- ALLK $0.26
- ASRT $0.85
- Average True Range (ATR)
- ALLK 0.11
- ASRT 0.03
- MACD
- ALLK -0.08
- ASRT 0.00
- Stochastic Oscillator
- ALLK 1.62
- ASRT 42.86
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.